"With one treatment, several viral infections such as dengue fever are treated simultaneously."
Clinical agreement signed with Vietnam National Forest Tropical Disease Hospital
[E-Daily Reporter Shin Min-joon] Hyundai Bio (048410) Science (Hyundai Bio) announced on the 30th that it will conduct the worlds first general-purpose antiviral drug Jeopardy Basket clinical trial. This basket clinical trial verifies the therapeutic effect of several viral infections at the same time with one treatment, not with the previous viral treatment clinical trial, which verifies the therapeutic effect of one infectious disease with one drug.
Hyundai Bio agreed to conduct simultaneous basket clinical trials for several viral infections that differ in family and species, including dengue fever, Zika, Chikungunya, COVID-19, and influenza A virus infection, with Vietnams National Tropical Disease Hospital (NHTD), a general-purpose antiviral drug developed by the company. Hyundai Bio signed a clinical agreement (MOU) with Vietnams National Tropical Disease Hospital on the 27th with the approval of the Vietnamese health authorities.
In June last year, Hyundai Bio announced the results of clinical trials of the COVID-19 treatment Jeopardy at the annual general meeting of the American Society of Microbiology in Houston, Texas, and suggested to the worlds medical community that "Only treating multiple viral infections with one drug can prepare for the future virus infection pandemic as well as the treatment of viral infections that do not currently have a cure."
Since then, Hyundai Bio has been accelerating the development of a universal antiviral drug called Jeopardy. Cell tests have shown that 33 viruses in 16 families, including COVID-19, AIDS, dengue, and Ebola, are effective antiviral substances, according to Hyundai Bio. However, focusing on niclosamide, which is not well absorbed by the body and has a short duration of maintaining an active drug concentration in the blood, the worlds first patented drug delivery technology has overcome the above two difficulties and recreated it as an oral antiviral drug containing niclosamide.
Through human clinical trials, animal experiments, and cell experiments, Hyundai Bio has demonstrated that the virus infection in animals and humans is also effective against viruses whose main ingredient is niclosamide. By conducting clinical trials on COVID-19, Hyundai Bio has demonstrated its safety and effectiveness.
According to Hyundai Bio, the results of this clinical trial are meaningful in that it is the first to show that if niclosamide is found to be effective, it can also treat a persons viral disease. Jeffty is currently in the process of phase 3 clinical trials for high-risk patients for COVID-19.
Hyundai Bio conducted an animal test to verify the efficacy of Jeopardy against H1N1, which belongs to influenza type A, which is expected to cause a future pandemic. As a result, it was confirmed that Jeopardys effect of reducing influenza virus levels was excellent. The results of the experiment are the first to reveal that Jeopardy, which was confirmed to be effective against COVID-19, is also effective against other family types of respiratory viruses in vivo, Hyundai Bio explained.
At the Health Experts Summit on Disease Prevention and Management held in Philadelphia on August 6, Hyundai Bio announced, "Only general-purpose antiviral drugs that treat multiple viral infections with a single drug can treat viral diseases that do not currently have a cure and prepare for future viral diseases such as bird flu."
This month, Hyundai Bio will also conduct a clinical trial with Professor Dr. David Smiths research team at the University of California-San Diego and Jefftys Long Covid researchers.
We hope that this clinical trial will open the way for treating many patients with tropical diseases suffering from the lack of a cure, said an official at Vietnams National Tropical Disease Hospital. "Jeftys clinical trial could be a new breakthrough in treating various viral diseases, including dengue fever," he added. "We will actively cooperate with this clinical trial so that Vietnam can become a hub for developing treatments for viral diseases."
Oh Sang-ki, CEO of Hyundai Bio, said, "This basket clinical trial will be the beginning of the era of general-purpose antiviral drugs that simultaneously treat multiple viral infections such as dengue fever with one treatment."
Shin Minjun (adonis@edaily.co.kr )